Acomplia Rimonabant is an oral prescription medication to treat obesity in an effectual manner. With Rimonabant as its active ingredient, Accomplia is developed and marketed by Sanofi-Aventis, a French pharmaceutical firm. Acomplia Rimonabant was recently launched in the UK weight loss drug market as a consequence of an agreement reached upon by 25-memeber European Union. Accomplia is Sold under brand name "Rimonabant" in UK and European union and as "Zimulti" in USA and Canada. How does Acomplia work?

Acomplia Rimonabant works by inhibiting the CB-1 receptors which are responsible for regulating food intake of the body. When these receptors are blocked, the normal appetite of the body decreases. This means you are satisfied even with consumption of small amounts of food. This activity, thereby sources weight loss. It is also beneficial in the cessation of smoking and improvement in obesity related cardio-metabolic risk factors.

Buy Acomplia (Rimonabant), the new age weight loss drug which is developed by world's third largest French pharmaceutical Sanofi-Aventis, to help ever growing number of obese population across the world. Acomplia Rimonabant (Acomplia/Zimulti) is recommend to those patients (BMI %u2265 30 kg/m2), or overweight patients (BMI > 27 kg/m2) with associated risk factors such as type 2 diabetes or dyslipidemia.

Now that a promising new prescription anti-obesity drug, rimonabant, is actually available in the U.K., Germany and 40 other countries, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans.

The drug, marketed in Europe as Acomplia, may ultimately be sold in the United States as Zimulti -- but that day appears several years off after an FDA advisory panel voted against sale of rimonabant in summer 2007 out of concern over its depressive side effects.

The Zimulti Acomplia Report, updated daily, will track the continuing efforts of Sanofi to get rimonabant approved for sale in the U.S. The Zimulti Acomplia Report also will provide news and reviews related to rimonabant Acomplia so those eager to try this new anti-obesity drug will have the latest information on availability, weight-loss results and side-effects.

"I'm confident in Acomplia because it is a unique product," Sanofi's head of research Marc Cluzel told reporters and analysts at a presentation on the company's research and development program.

While Acomplia was launched in Europe in 2006 and is also available in a handful of other countries, Sanofi withdrew its application in the United States after an FDA advisory panel unanimously recommended against approving the drug out of concern over side-effects including depression and suicidality.

Cluzel said Sanofi expects to refile its application with the FDA after longer-term data on the use of Acomplia has been gathered from the large CRESCENDO trial, which got underway in December 2005.

Sanofi said it has enrolled approximately 11,000 of the 17,000 participants planned for this trial, and indicated it expects to have data from this study available to share with the FDA in 2010.